Company Performance - Badger Meter (BMI) closed at $181.26, reflecting a -1.03% change from the previous day, underperforming the S&P 500 which gained 0.46% [1] - Over the last month, Badger Meter's shares increased by 2.99%, lagging behind the Computer and Technology sector's gain of 4.54% and the S&P 500's gain of 4.22% [2] - The upcoming earnings per share (EPS) is projected at $1.14, indicating a 9.62% increase year-over-year, with revenue expected to be $231.61 million, a 12.88% increase compared to the same quarter last year [3] - For the full year, earnings are projected at $4.79 per share and revenue at $927.59 million, representing increases of +13.24% and +12.22% respectively from the prior year [4] Analyst Insights - Recent revisions to analyst forecasts for Badger Meter should be monitored, as they reflect near-term business trends and analysts' confidence in the company's profitability [5] - The Zacks Rank system, which evaluates estimate changes, currently ranks Badger Meter at 4 (Sell), with the consensus EPS estimate having decreased by 0.13% over the past month [6][7] Valuation Metrics - Badger Meter is trading at a Forward P/E ratio of 38.22, which is a premium compared to the industry average Forward P/E of 24.25 [8] - The company has a PEG ratio of 3.02, higher than the industry average PEG ratio of 2.18, indicating a higher valuation relative to expected earnings growth [8] Industry Context - The Instruments - Control industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 102, placing it in the top 42% of over 250 industries [9]

Company Performance - T. Rowe Price (TROW) stock increased by 1.47% to $104.80, outperforming the S&P 500's daily gain of 0.64% [1] - Over the past month, TROW shares appreciated by 2.96%, underperforming the Finance sector's gain of 4.92% and the S&P 500's gain of 3% [1] Upcoming Financial Results - T. Rowe Price is expected to report an EPS of $2.47, reflecting a 16.51% increase from the prior-year quarter [2] - The consensus estimate for revenue is $1.91 billion, up 4.94% from the prior-year quarter [2] Full Year Projections - For the full year, earnings are projected at $9.76 per share and revenue at $7.3 billion, showing increases of 4.61% and 2.84% respectively from the previous year [3] - Recent analyst estimate revisions indicate confidence in T. Rowe Price's business performance and profit potential [3] Valuation Metrics - T. Rowe Price has a Forward P/E ratio of 10.58, which is lower than the industry average of 12.65, suggesting it is trading at a discount [6] - The company has a PEG ratio of 2.79, compared to the industry average PEG ratio of 1.29 [7] Industry Context - The Financial - Investment Management industry, part of the Finance sector, holds a Zacks Industry Rank of 162, placing it in the bottom 35% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Zoetis (ZTS) closed at $123.78, reflecting a +1.26% change from the previous day's closing price, outperforming the S&P 500's gain of 0.64% [1] - The stock has increased by 0.15% over the past month, underperforming the Medical sector's gain of 2.25% and the S&P 500's gain of 3% [1] Upcoming Earnings - Analysts forecast Zoetis to report an EPS of $1.4, indicating no change from the same quarter last year, with expected quarterly revenue of $2.36 billion, up 1.89% year-over-year [2] Full-Year Estimates - The Zacks Consensus Estimates for Zoetis project earnings of $6.34 per share and revenue of $9.44 billion, representing year-over-year increases of +7.09% and +2%, respectively [3] Analyst Estimates and Stock Performance - Recent changes in analyst estimates for Zoetis are crucial as they often indicate shifts in near-term business trends, with positive revisions suggesting a favorable business outlook [3] - The Zacks Rank system, which incorporates estimate changes, has shown that stocks ranked 1 (Strong Buy) have yielded an average annual return of +25% since 1988 [4][5] Valuation Metrics - Zoetis is currently trading at a Forward P/E ratio of 19.3, which is lower than the industry average of 19.43 [6] - The company has a PEG ratio of 2.66, compared to the Medical - Drugs industry average PEG ratio of 1.17 [6] Industry Ranking - The Medical - Drugs industry, which includes Zoetis, holds a Zacks Industry Rank of 70, placing it in the top 29% of over 250 industries [7]

Company Performance - DaVita HealthCare (DVA) closed at $116.51, with a daily increase of +1.14%, outperforming the S&P 500's gain of 0.64% [1] - Over the past month, DVA shares have decreased by 4.2%, underperforming the Medical sector's increase of 2.25% and the S&P 500's increase of 3% [1] Earnings Projections - The upcoming EPS for DaVita HealthCare is projected at $3.34, indicating a significant increase of 49.11% compared to the same quarter last year [2] - Revenue is expected to reach $3.53 billion, reflecting a growth of 6.99% year-over-year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are projected at $10.52 per share, representing an increase of 8.68% from the previous year [3] - Revenue for the fiscal year is estimated at $13.55 billion, indicating a growth of 5.75% compared to the prior year [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for DaVita HealthCare should be monitored, as they often reflect short-term business trends [4] - Positive estimate revisions are interpreted as favorable indicators for the business outlook [4] Zacks Rank and Valuation - DaVita HealthCare currently holds a Zacks Rank of 3 (Hold), with the EPS estimate remaining unchanged over the last 30 days [6] - The company is trading at a Forward P/E ratio of 10.95, which is below the industry average of 19.65 [7] - DaVita has a PEG ratio of 0.87, compared to the industry average PEG ratio of 1.96 [7] Industry Context - The Medical - Outpatient and Home Healthcare industry ranks in the top 22% of all industries, with a current Zacks Industry Rank of 53 [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Company Performance - Organon (OGN) closed at $6.98, reflecting a +2.2% change from the previous day's closing price, outperforming the S&P 500's gain of 0.64% [1] - Over the past month, Organon shares have decreased by 5.14%, while the Medical sector and S&P 500 have increased by 2.25% and 3% respectively [1] Upcoming Financial Results - Organon is expected to report an EPS of $0.74, indicating a 17.78% decline compared to the same quarter last year [2] - Revenue is projected to be $1.53 billion, showing a 3.84% decrease from the year-ago quarter [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $3.78 per share and revenue at $6.24 billion, reflecting changes of -8.03% and -2.55% respectively from the previous year [3] - Recent analyst estimate revisions suggest a positive outlook on Organon's business operations and profit generation capabilities [3] Valuation Metrics - Organon has a Forward P/E ratio of 1.81, which is significantly lower than the industry average Forward P/E of 15.44 [6] - The company has a PEG ratio of 1.4, compared to the Medical Services industry's average PEG ratio of 1.67 [7] Industry Ranking - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 156, placing it in the bottom 37% of over 250 industries [8] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [8]

Investors interested in stocks from the Banks - Foreign sector have probably already heard of Deutsche Bank (DB) and National Australia Bank Ltd. (NABZY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while ...

Core Viewpoint - Cardinal Health's stock performance has been mixed, with a recent increase but a decline over the past month, and upcoming earnings are anticipated to show significant growth in both EPS and revenue [1][2][3]. Company Performance - Cardinal Health's stock rose by 1.93% to $202.95, outperforming the S&P 500's gain of 0.88% [1] - Over the past month, the stock has decreased by 4.23%, underperforming the Medical sector's gain of 1.2% and the S&P 500's gain of 2.48% [1]. Earnings Forecast - The upcoming earnings report is expected to show an EPS of $2.31, reflecting a 19.69% increase from the same quarter last year [2]. - Revenue is forecasted to reach $64.07 billion, indicating a 15.94% rise compared to the previous year [2]. Annual Estimates - For the annual period, earnings are projected at $9.86 per share, with revenue expected to be $258.58 billion, representing increases of 19.66% and 16.18% respectively from last year [3]. Analyst Estimates - Recent modifications to analyst estimates for Cardinal Health are crucial, as positive revisions indicate optimism regarding business and profitability [3]. - The Zacks Consensus EPS estimate has seen a slight downward shift of 0.17% over the past month, and Cardinal Health currently holds a Zacks Rank of 3 (Hold) [5]. Valuation Metrics - Cardinal Health has a Forward P/E ratio of 20.19, which is higher than the industry average of 17.72 [6]. - The company’s PEG ratio stands at 1.45, compared to the Medical - Dental Supplies industry's average PEG ratio of 2.36 [6]. Industry Context - The Medical - Dental Supplies industry, part of the Medical sector, has a Zacks Industry Rank of 151, placing it in the bottom 39% of over 250 industries [7]. - Historically, industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [7].

What is the future of the AI trade and how are you playing it next year. Art, is it Mac 7 or Bust for you. >> Uh, it's not.And I'll tell you this, I think this was the year after uh 3 years of AI u being rolled out and the revolution starting where investors clearly had to start to differentiate. And the differentiation point really came to the fact that if you're spending massive amounts of money on capex to build out your large language model, that's fine if it's coming from free cash flow. If you're putt ...

Core Viewpoint - Camtek's stock performance has been relatively weak compared to major indices, but it has shown resilience over the past month with a positive trend in share price [1][2]. Financial Performance - Upcoming financial results are expected to show an EPS of $0.83, reflecting a 7.79% increase year-over-year, with projected revenue of $127.21 million, up 8.46% from the same quarter last year [3]. - For the full year, earnings are projected at $3.21 per share and revenue at $495.14 million, indicating increases of 13.43% and 15.36% respectively compared to the previous year [4]. Analyst Sentiment - Recent upward revisions in analyst estimates suggest a positive outlook for Camtek's business operations and profitability [5]. - The Zacks Rank system currently rates Camtek as 3 (Hold), with a slight increase of 0.14% in the consensus EPS projection over the past 30 days [7]. Valuation Metrics - Camtek is trading at a Forward P/E ratio of 32.15, which is lower than the industry average of 42.39, indicating a potential discount [8]. - The company has a PEG ratio of 2.06, compared to the industry average of 1.97, suggesting that while the stock may be undervalued based on P/E, it is slightly higher when considering growth expectations [9]. Industry Context - The Electronics - Measuring Instruments industry, part of the Computer and Technology sector, holds a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries, indicating strong performance potential [10].

Company Performance - ASML closed at $1,036.31, reflecting a +2.06% increase from the previous day, outperforming the S&P 500's daily gain of 0.79% [1] - Over the past month, ASML shares have decreased by 2.3%, while the Computer and Technology sector has lost 0.85% and the S&P 500 has gained 0.87% [1] Earnings Forecast - ASML is expected to report an EPS of $8.84, indicating a 21.1% growth compared to the same quarter last year [2] - Revenue is forecasted to be $11.06 billion, representing an 11.9% increase compared to the corresponding quarter of the previous year [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of $29.01 per share and revenue of $37.64 billion, reflecting year-over-year changes of +39.34% and +23.21%, respectively [3] - Recent changes to analyst estimates for ASML may indicate shifting business dynamics, with positive revisions suggesting a favorable business outlook [3] Valuation Metrics - ASML has a Forward P/E ratio of 35, which is a premium compared to its industry's Forward P/E of 33.91 [6] - The company has a PEG ratio of 1.58, while the Semiconductor Equipment - Wafer Fabrication industry has an average PEG ratio of 1.28 [6] Industry Context - The Semiconductor Equipment - Wafer Fabrication industry is part of the Computer and Technology sector and holds a Zacks Industry Rank of 6, placing it in the top 3% of over 250 industries [7] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]